Top 10 Biotechnology Companies - SWOT Analysis, Competitive Benchmarking, Financial Analysis and RD Pipeline

Top 10 Biotechnology Companies - SWOT Analysis, Competitive Benchmarking, Financial Analysis and R&D Pipeline

Summary

GBI Research, the leading business intelligence provider, has released its latest research, “Top 10 Biotechnology Companies - SWOT Analysis, Competitive Benchmarking, Financial Analysis and R&D Pipeline”, which provides an insight into the global biotechnology industry and analyzes the competitive positioning of the top 10 companies in the industry. This pharmaceutical and healthcare report estimates the market size of the global biotechnology industry and its future prospects. It benchmarks the leading companies in the biotechnology industry on selected parameters to analyze their competitive positioning in the market. The report analyzes the future landscape of the biotechnology industry by forecasting the revenues of leading companies to 2012. For each company the report analyzes the financial strength, product portfolio, pipeline strength and therapeutic focus of its R&D activities. It critically examines the strengths and weaknesses of individual companies and the opportunities and threats facing them.

This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GBI Research’s team of industry experts.

Scope

The report analyses the competitive landscape of the biotechnology industry, R&D strategies and pipeline of the top 10 players, and strengths, weaknesses, opportunities and threats facing these companies. Its Scope includes

• Market size of the global biotechnology industry and coverage of the changing competitive landscape from 2008 to 2012.
• Review of key industry drivers and restraints which are likely to impact the global biotechnology industry in the future.
• Analysis of the competitive positioning of the top 10 biotechnology companies globally.
• Analysis of pipeline products in the global biotech market by therapy area like cancer, infectious diseases, respiratory disorders, autoimmune disorders, and product classes.
• Financial analysis including annual revenues of top 10 companies from 2004 to 2008, with forecasts to 2012.

SWOT analysis, DuPont analysis and financial benchmarking of the top 10 biotech companies.

Analysis of the therapeutic focus, marketed products and product pipeline of top 10 biotech companies.

Reasons to buy

The report will enhance your decision making capability in a more rapid and time sensitive manner. It will allow you to:

• Develop a clear knowledge and understanding of the competitive landscape and how this will change in the coming years.
• Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
• Effectively plan your M&A and partnership strategies by identifying companies with the most promising pipeline.
• Make more informed business decisions from the insightful and in-depth analysis of the key strategies to be followed by competitors.
• Effectively plan your investment strategies by identifying companies with maximum investment potential.
• Identify key winners and losers and who is best positioned to take advantage of the emerging market opportunities.

Contents

1.1 List of Tables
1.2 List of Figures

2 INTRODUCTION

2.1 GBI Research Report Guidance

3 GLOBAL BIOTECHNOLOGY INDUSTRY – MARKET CHARACTERIZATION

3.1 Global Biotechnology Industry – Market Size
3.2 Top 10 Companies – Market Forecast
3.3 Therapeutic Focus of the Biotechnology Industry
3.4 Global Biotechnology Industry – Growth Drivers and Restraints
  3.4.1 Growth Drivers
  3.4.2 Restraints

4 TOP 10 BIOTECHNOLOGY COMPANIES – COMPETITIVE LANDSCAPE

4.1 Competitive Landscape Framework
4.2 Financial Benchmarking
  4.2.1 Earnings per Share
  4.2.2 Net Profit Margin
  4.2.3 Current Ratio
  4.2.4 Debt to Equity ratio
  4.2.5 Asset Turnover Ratio
4.3 R&D Productivity Framework

5 GLOBAL BIOTECHNOLOGY INDUSTRY – STRATEGIC CONSOLIDATIONS

5.1 Pharma Biotech Space – Deals Analysis (2008)
5.2 Increasing Interest of Big Pharma Companies in the Biotech Industry

6 TOP 10 BIOTECHNOLOGY COMPANIES – AMGEN

6.1 Company Overview
  6.1.1 Introduction
  6.1.2 Business Description
6.2 Strategic Positioning
  6.2.1 SWOT Analysis
6.3 Financial Analysis
  6.3.1 Revenue Analysis and Forecasts
  6.3.2 Ratio Analysis
  6.3.3 DuPont Analysis
6.4 Marketed Products
  6.4.1 Key Marketed Products
6.5 R&D Strategies
  6.5.1 Therapeutic Focus
  6.5.2 R&D Productivity
6.6 Product Pipeline
  6.6.1 Overview
  6.6.2 Key Pipeline Products
6.7 Licensing Agreements
  6.7.1 Overview

7 TOP 10 BIOTECHNOLOGY COMPANIES – GENENTECH (ROCHE)

7.1 Company Overview
  7.1.1 Introduction
  7.1.2 Business Description
7.2 Strategic Positioning
  7.2.1 SWOT Analysis
7.3 Financial Analysis
  7.3.1 Revenue Analysis and Forecasts
  7.3.2 Ratio Analysis
  7.3.3 DuPont Analysis
7.4 Marketed Products
  7.4.1 Key Marketed Products
7.5 R&D Strategies
  7.5.1 Therapeutic Focus
  7.5.2 R&D Productivity
7.6 Product Pipeline
  7.6.1 Overview
  7.6.2 Key Pipeline Products
7.7 Licensing Agreements
  7.7.1 Overview

8 TOP 10 BIOTECHNOLOGY COMPANIES – GILEAD SCIENCES

8.1 Company Overview
  8.1.1 Introduction
  8.1.2 Business Description
8.2 Strategic Positioning
  8.2.1 SWOT Analysis
8.3 Financial Analysis
  8.3.1 Revenue Analysis and Forecasts
  8.3.2 Ratio Analysis
  8.3.3 DuPont Analysis
8.4 Marketed Products
  8.4.1 Key Marketed Products
8.5 R&D Strategies
  8.5.1 Therapeutic Focus
  8.5.2 R&D Productivity
8.6 Product Pipeline
  8.6.1 Overview
  8.6.2 Key Pipeline Products
8.7 Licensing Agreements
  8.7.1 Overview

9 TOP 10 BIOTECHNOLOGY COMPANIES – UCB PHARMA

9.1 Company Overview
  9.1.1 Introduction
  9.1.2 Business Description
9.2 Strategic Positioning
  9.2.1 SWOT Analysis
9.3 Financial Analysis
  9.3.1 Revenue Analysis and Forecasts
  9.3.2 Ratio Analysis
  9.3.3 DuPont Analysis
9.4 Marketed Products
  9.4.1 Key Marketed Products
9.5 R&D Strategies
  9.5.1 Therapeutic Focus
  9.5.2 R&D Productivity
9.6 Product Pipeline
  9.6.1 Overview
  9.6.2 Key Pipeline Products
9.7 Licensing Agreements
  9.7.1 Overview

10 TOP 10 BIOTECHNOLOGY COMPANIES – GENZYME

10.1 Company Overview
  10.1.1 Introduction
  10.1.2 Business Description
10.2 Strategic Positioning
  10.2.1 SWOT Analysis
10.3 Financial Analysis
  10.3.1 Revenue Analysis and Forecasts
  10.3.2 Ratio Analysis
  10.3.3 DuPont Analysis
10.4 Marketed Products
  10.4.1 Key Marketed Products
10.5 R&D Strategies
  10.5.1 Therapeutic Focus
  10.5.2 R&D Productivity
10.6 Product Pipeline
  10.6.1 Overview
  10.6.2 Key Pipeline Products
10.7 Licensing Agreements
  10.7.1 Overview

11 TOP 10 BIOTECHNOLOGY COMPANIES – BIOGEN IDEC

11.1 Company Overview
  11.1.1 Introduction
  11.1.2 Business Description
11.2 Strategic Positioning
  11.2.1 SWOT Analysis
11.3 Financial Analysis
  11.3.1 Revenue Analysis and Forecasts
  11.3.2 Ratio Analysis
  11.3.3 DuPont Analysis
11.4 Marketed Products
  11.4.1 Key Marketed Products
11.5 R&D Strategies
  11.5.1 Therapeutic Focus
  11.5.2 R&D Productivity
11.6 Product Pipeline
  11.6.1 Overview
  11.6.2 Key Pipeline Products
11.7 Licensing Agreements
  11.7.1 Overview

12 TOP 10 BIOTECHNOLOGY COMPANIES – CSL LIMITED

12.1 Company Overview
  12.1.1 Introduction
  12.1.2 Business Description
12.2 Strategic Positioning
  12.2.1 SWOT Analysis
12.3 Financial Analysis
  12.3.1 Revenue Analysis and Forecasts
  12.3.2 Ratio Analysis
  12.3.3 DuPont Analysis
12.4 Marketed Products
  12.4.1 Key Marketed Products
12.5 R&D Strategies
  12.5.1 Therapeutic Focus
  12.5.2 R&D Productivity
12.6 Product Pipeline
  12.6.1 Overview
  12.6.2 Key Pipeline Products
12.7 Licensing Agreements
  12.7.1 Overview

13 TOP 10 BIOTECHNOLOGY COMPANIES – CELGENE

13.1 Company Overview
  13.1.1 Introduction
  13.1.2 Business Description
13.2 Strategic Positioning
  13.2.1 SWOT Analysis
13.3 Financial Analysis
  13.3.1 Revenue Analysis and Forecasts
  13.3.2 Ratio Analysis
  13.3.3 DuPont Analysis
13.4 Marketed Products
  13.4.1 Key Marketed Products
13.5 R&D Strategies
  13.5.1 Therapeutic Focus
  13.5.2 R&D Productivity
13.6 Product Pipeline
  13.6.1 Overview
  13.6.2 Key Pipeline Products
13.7 Licensing Agreements
  13.7.1 Overview

14 TOP 10 BIOTECHNOLOGY COMPANIES – CEPHALON

14.1 Company Overview
  14.1.1 Introduction
  14.1.2 Business Description
14.2 Strategic Positioning
  14.2.1 SWOT Analysis
14.3 Financial Analysis
  14.3.1 Revenue Analysis and Forecasts
  14.3.2 Ratio Analysis
  14.3.3 DuPont Analysis
14.4 Marketed Products
  14.4.1 Key Marketed Products
14.5 R&D Strategies
  14.5.1 Therapeutic Focus
  14.5.2 R&D Productivity
14.6 Product Pipeline
  14.6.1 Overview
  14.6.2 Key Pipeline Products
14.7 Licensing Agreements
  14.7.1 Overview

15 TOP 10 BIOTECHNOLOGY COMPANIES – ACTELION

15.1 Company Overview
  15.1.1 Introduction
  15.1.2 Business Description
15.2 Strategic Positioning
  15.2.1 SWOT Analysis
15.3 Financial Analysis
  15.3.1 Revenue Analysis and Forecasts
  15.3.2 Ratio Analysis
  15.3.3 DuPont Analysis
15.4 Marketed Products
  15.4.1 Key Marketed Products
15.5 R&D Strategies
  15.5.1 Therapeutic Focus
  15.5.2 R&D Productivity
15.6 Product Pipeline
  15.6.1 Overview
  15.6.2 Key Pipeline Products
15.7 Licensing Agreements
  15.7.1 Overview

16 TOP 10 BIOTECHNOLOGY COMPANIES – APPENDIX

16.1 Market Definitions
16.2 Abbreviations
16.3 Research Methodology
  16.3.1 Coverage
  16.3.2 Secondary Research
  16.3.3 Primary Research
  16.3.4 Expert Panel Validation
16.4 Contact Us
16.5 Disclaimer
16.6 Sources

1.1 LIST OF TABLES

Table 1: Top 10 Biotechnology Companies, Global, Annual Revenues, ($m), 2008
Table 2: Global, Top 25 Biologic Drugs by Annual Sales. 2008
Table 3: Top 10 Biotechnology Companies, Global, Revenue Forecast, ($m), 2008-2012
Table 4: Top 10 Biotechnology Companies, Global, Company Rankings, 2008-2012
Table 5: Top 10 Biotechnology Companies, Global, Rankings by Strength of Marketed and Pipeline Products, 2008
Table 6: Top 10 Biotechnology Companies, Global, Earnings per Share, ($), 2008
Table 7: Top 10 Biotechnology Companies, Global, Net Profit Margin, (%), 2008
Table 8: Top 10 Biotechnology Companies, Global, Current Ratio, 2008
Table 9: Top 10 Biotechnology Companies, Global, Debt to Equity Ratio, 2008
Table 10: Top 10 Biotechnology Companies, Global, Asset Turnover Ratio, 2008
Table 11: Top 10 Biotechnology Companies, Global, Rankings by Strength of Pipeline Products in Each Therapy Area (1), 2008
Table 12: Top 10 Biotechnology Companies, Global, Rankings by Strength of Pipeline Products in Each Therapy Area (2), 2008
Table 13: Biotechnology Industry, Global, Key M&A Deals in 2008
Table 14: Global, Value of Drugs Going Off-Patent by Therapeutic Area, ($m), 2009–2014
Table 15: Amgen Inc., Historical Revenue, ($m), 2004-2008
Table 16: Amgen Inc., Revenue Forecast, ($m), 2008-2012
Table 17: Amgen Inc., Net Income and R&D Expense, ($m), 2004-2008
Table 18: Equity Ratios for Amgen Inc., ($), 2004-2008
Table 19: Profitability Ratios for Amgen Inc., (%), 2004-2008
Table 20: Liquidity Ratios for Amgen Inc., 2004-2008
Table 21: Leverage Ratios for Amgen Inc., 2004-2008
Table 22: Efficiency Ratios for Amgen Inc., 2004-2008
Table 23: Expenditure on R&D for Amgen Inc., ($m), 2004-2008
Table 24: Phase-wise Analysis of Amgen R&D Pipeline, 2009
Table 25: Amgen Inc., Licensing Agreements for Drugs, 2008-July 2009
Table 26: Genentech, Historical Revenue, ($m), 2004-2008
Table 27: Genentech, Revenue Forecast, ($m), 2008-2012
Table 28: Genentech, Net Income and R&D Expense, ($m), 2004-2008
Table 29: Equity Ratios for Genentech, ($), 2004-2008
Table 30: Profitability Ratios for Genentech, (%), 2004-2008
Table 31: Liquidity Ratios for Genentech, 2004-2008
Table 32: Leverage Ratios for Genentech, 2004-2008
Table 33: Efficiency Ratios for Genentech, 2004-2008
Table 34: Expenditure on R&D for Genentech, ($m), 2004-2008
Table 35: Phase-wise Analysis of Genentech R&D Pipeline, 2009
Table 36: Genentech, Licensing Agreements for Drugs, 2008-July 2009
Table 37: Gilead, Historical Revenue, ($m), 2004-2008
Table 38: Gilead, Revenue Forecast, ($m), 2008-2012
Table 39: Gilead, Net Income and R&D Expense, ($m), 2004-2008
Table 40: Equity Ratios for Gilead, ($), 2004-2008
Table 41: Profitability Ratios for Gilead, (%), 2004-2008
Table 42: Liquidity Ratios for Gilead, 2004-2008
Table 43: Leverage Ratios for Gilead, 2004-2008
Table 44: Efficiency Ratios for Gilead, 2004-2008
Table 45: Expenditure on R&D by Gilead, ($m), 2004-2008
Table 46: Phase-wise Analysis of Gilead R&D Pipeline, 2009
Table 47: Gilead, Licensing Agreements for Drugs, 2008-July 2009
Table 48: UCB Pharma, Historical Revenue, ($m), 2004-2008
Table 49: UCB Pharma, Revenue Forecast, ($m), 2008-2012
Table 50: UCB Pharma, Net Income and R&D Expense, ($m), 2004-2008
Table 51: Equity Ratios for UCB Pharma, ($), 2004-2008
Table 52: Profitability Ratios for UCB Pharma, (%), 2004-2008
Table 53: Liquidity Ratios for UCB Pharma, 2004-2008
Table 54: Leverage Ratios for UCB Pharma, 2004-2008
Table 55: Efficiency Ratios for UCB Pharma, 2004-2008
Table 56: Expenditure on R&D by UCB Pharma, ($m), 2004-2008
Table 57: Phase-wise Analysis of UCB Pharma R&D Pipeline, 2009
Table 58: UCB Pharma, Licensing Agreements for Drugs, 2008-July 2009
Table 59: Genzyme, Historical Revenue, ($m), 2004-2008
Table 60: Genzyme, Revenue Forecast, ($m), 2008-2012
Table 61: Genzyme, Net Income and R&D Expense, ($m), 2004-2008
Table 62: Equity Ratios for Genzyme, ($), 2004-2008
Table 63: Profitability Ratios for Genzyme, (%), 2004-2008
Table 64: Liquidity Ratios for Genzyme, 2004-2008
Table 65: Leverage Ratios for Genzyme, 2004-2008
Table 66: Efficiency Ratios for Genzyme, 2004-2008
Table 67: Expenditure on R&D by Genzyme, ($m), 2004-2008
Table 68: Phase-wise Analysis of Genzyme R&D Pipeline, 2009
Table 69: Genzyme, Licensing Agreements for Drugs, 2008-July 2009
Table 70: Biogen Idec, Historical Revenue, ($m), 2004-2008
Table 71: Biogen Idec, Revenue Forecast, ($m), 2008-2012
Table 72: Biogen Idec, Net Income and R&D Expense, ($m), 2004-2008
Table 73: Equity Ratios for Biogen Idec, ($), 2004-2008
Table 74: Profitability Ratios for Biogen Idec, (%), 2004-2008
Table 75: Liquidity Ratios for Biogen Idec, 2004-2008
Table 76: Leverage Ratios for Biogen Idec, 2004-2008
Table 77: Efficiency Ratios for Biogen Idec, 2004-2008
Table 78: Expenditure on R&D for Biogen Idec, ($m), 2004-2008
Table 79: Phase-wise Analysis of Biogen Idec R&D Pipeline, 2009
Table 80: Biogen Idec, Licensing Agreements for Drugs, 2008-July 2009
Table 81: CSL Limited, Historical Revenue, ($m), 2005-2009
Table 82: CSL Limited, Revenue Forecast, ($m), 2009-2013
Table 83: CSL Limited, Net Income and R&D Expense, ($m), 2005-2009
Table 84: Equity Ratios for CSL Limited, ($), 2005-2009
Table 85: Profitability Ratios for CSL Limited, (%), 2005-2009
Table 86: Liquidity Ratios for CSL Limited, 2005-2009
Table 87: Leverage Ratios for CSL Limited, 2005-2009
Table 88: Efficiency Ratios for CSL Limited, 2005-2009
Table 89: Expenditure on R&D by CSL Limited, ($m), 2005-2009
Table 90: Phase-wise Analysis of CSL Limited R&D Pipeline, 2009
Table 91: CSL Limited, Licensing Agreements for Drugs, 2008-July 2009
Table 92: Celgene, Historical Revenue, ($m), 2004-2008
Table 93: Celgene, Revenue Forecast, ($m), 2008-2012
Table 94: Celgene, Net Income and R&D Expense, ($m), 2004-2008
Table 95: Equity Ratios for Celgene, ($), 2004-2008
Table 96: Profitability Ratios for Celgene, (%), 2004-2008
Table 97: Liquidity Ratios for Celgene, 2004-2008
Table 98: Leverage Ratios for Celgene, 2004-2008
Table 99: Efficiency Ratios for Celgene, 2004-2008
Table 100: Expenditure on R&D by Celgene, ($m), 2004-2008
Table 101: Phase-wise Analysis of Celgene R&D Pipeline, 2009
Table 102: Celgene, Licensing Agreements for Drugs, 2008-July 2009
Table 103: Cephalon, Historical Revenue, ($m), 2004-2008
Table 104: Cephalon, Revenue Forecast, ($m), 2008-2012
Table 105: Cephalon, Net Income and R&D Expense, ($m), 2004-2008
Table 106: Equity Ratios for Cephalon, ($), 2004-2008
Table 107: Profitability Ratios for Cephalon, (%), 2004-2008
Table 108: Liquidity Ratios for Cephalon, 2004-2008
Table 109: Leverage Ratios for Cephalon, 2004-2008
Table 110: Efficiency Ratios for Cephalon, 2004-2008
Table 111: Expenditure on R&D for Cephalon, ($m), 2004-2008
Table 112: Phase-wise Analysis of Cephalon R&D Pipeline, 2009
Table 113: Cephalon, Licensing Agreements for Drugs, 2008-July 2009
Table 114: Actelion, Historical Revenue, ($m), 2004-2008
Table 115: Actelion, Revenue Forecast, ($m), 2008-2012
Table 116: Actelion, Net Income and R&D Expense, ($m), 2004-2008
Table 117: Equity Ratios for Actelion, ($), 2004-2008
Table 118: Profitability Ratios for Actelion, (%), 2004-2008
Table 119: Liquidity Ratios for Actelion, 2004-2008
Table 120: Leverage Ratios for Actelion, 2004-2008
Table 121: Efficiency Ratios for Actelion, 2004-2008
Table 122: Expenditure on R&D by Actelion, ($m), 2004-2008
Table 123: Phase-wise Analysis of Actelion R&D Pipeline, 2009
Table 124: Actelion, Licensing Agreements for Drugs, 2008-July 2009

1.2 LIST OF FIGURES

Figure 1: Top 10 Biotechnology Companies, Global, Annual Revenues, ($m), 2008
Figure 2: Top 10 Biotechnology Companies, Global, Revenue Forecast, ($m), 2008-2012
Figure 3: Global, Biotech Pipeline Drugs by Therapy Areas, (%), 2008
Figure 4: Global, Biotech Pipeline Drugs by Product Classes, 2008
Figure 5: Biotechnology Industry, Global, Growth Drivers and Restraints,2008
Figure 6: Top 10 Biotechnology Companies, Global, Competitive Positioning, 2008
Figure 7: Top 10 Biotechnology Companies, Global, Competitive Landscape Framework, 2008
Figure 8: Top 10 Biotechnology Companies, Global, R&D Productivity Framework, 2008
Figure 9: Global, Value of Drugs Going Off-Patent by Therapeutic Area, ($m), 2009–2014
Figure 10: SWOT Analysis of Amgen Inc.
Figure 11: Amgen Inc., Annual Revenue Forecasts, ($m), 2004-2012
Figure 12: Amgen Inc., Net Income and R&D Expense, ($m), 2004-2008
Figure 13: Amgen Inc., Earnings per Share, ($), 2004-2008
Figure 14: Amgen Inc., Net Profit Margin, (%), 2004-2008
Figure 15: Amgen Inc., Current Ratio, 2004-2008
Figure 16: Amgen Inc., Debt to Equity Ratio, 2004-2008
Figure 17: Amgen Inc., Return on Equity, (%), 2004-2008
Figure 18: DuPont Analysis for Amgen Inc., 2004-2008
Figure 19: Therapeutic Focus of Amgen R&D Pipeline, 2009
Figure 20: R&D Productivity for Amgen Inc., 2004-2008
Figure 21: Phase-wise Analysis of Amgen R&D Pipeline, 2009
Figure 22: SWOT Analysis of Genentech
Figure 23: Genentech, Annual Revenue Forecasts, ($m), 2004-2012
Figure 24: Genentech, Net Income and R&D Expense, ($m), 2004-2008
Figure 25: Genentech, Earnings per Share, ($), 2004-2008
Figure 26: Genentech, Net Profit Margin, (%), 2004-2008
Figure 27: Genentech, Current Ratio, 2004-2008
Figure 28: Genentech, Debt to Equity Ratio, 2004-2008
Figure 29: Genentech, Return on Equity, (%), 2004-2008
Figure 30: DuPont Analysis for Genentech, 2004-2008
Figure 31: Therapeutic Focus of Genentech R&D Pipeline, 2009
Figure 32: R&D Productivity for Genentech, 2004-2008
Figure 33: Phase-wise Analysis of Genentech R&D Pipeline, 2009
Figure 34: SWOT Analysis of Gilead
Figure 35: Gilead, Annual Revenue Forecasts, ($m), 2004-2012
Figure 36: Gilead, Net Income and R&D Expense, ($m), 2004-2008
Figure 37: Gilead, Earnings per Share, ($), 2004-2008
Figure 38: Gilead, Net Profit Margin, (%), 2004-2008
Figure 39: Gilead, Current Ratio, 2004-2008
Figure 40: Gilead, Debt to Equity Ratio, 2004-2008
Figure 41: Gilead, Return on Equity, (%), 2004-2008
Figure 42: DuPont Analysis for Gilead, 2004-2008
Figure 43: Therapeutic Focus of Gilead R&D Pipeline, 2009
Figure 44: R&D Productivity for Gilead, 2004-2008
Figure 45: Phase-wise Analysis of Gilead R&D Pipeline, 2009
Figure 46: SWOT Analysis of UCB Pharma
Figure 47: UCB Pharma, Annual Revenue Forecasts, ($m), 2004-2012
Figure 48: UCB Pharma, Net Income and R&D Expense, ($m), 2004-2008
Figure 49: UCB Pharma, Earnings per Share, ($), 2004-2008
Figure 50: UCB Pharma, Net Profit Margin, (%), 2004-2008
Figure 51: UCB Pharma, Current Ratio, 2004-2008
Figure 52: UCB Pharma, Debt to Equity Ratio, 2004-2008
Figure 53: UCB Pharma, Return on Equity, (%), 2004-2008
Figure 54: DuPont Analysis for UCB Pharma, 2004-2008
Figure 55: Therapeutic Focus of UCB Pharma R&D Pipeline, 2009
Figure 56: R&D Productivity for UCB Pharma, 2004-2008
Figure 57: Phase-wise Analysis of UCB Pharma R&D Pipeline, 2009
Figure 58: SWOT Analysis of Genzyme
Figure 59: Genzyme, Annual Revenue Forecasts, ($m), 2004-2012
Figure 60: Genzyme, Net Income and R&D Expense, ($m), 2004-2008
Figure 61: Genzyme, Earnings per Share, ($), 2004-2008
Figure 62: Genzyme, Net Profit Margin, (%), 2004-2008
Figure 63: Genzyme, Current Ratio, 2004-2008
Figure 64: Genzyme, Debt to Equity Ratio, 2004-2008
Figure 65: Genzyme, Return on Equity, (%), 2004-2008
Figure 66: DuPont Analysis for Genzyme, 2004-2008
Figure 67: Therapeutic Focus of Genzyme R&D Pipeline, 2009
Figure 68: R&D Productivity for Genzyme, 2004-2008
Figure 69: Phase-wise Analysis of Genzyme R&D Pipeline, 2009
Figure 70: SWOT Analysis of Biogen Idec
Figure 71: Biogen Idec, Annual Revenue Forecasts, ($m), 2004-2012
Figure 72: Biogen Idec, Net Income and R&D Expense, ($m), 2004-2008
Figure 73: Biogen Idec, Earnings per Share, ($), 2004-2008
Figure 74: Biogen Idec, Net Profit Margin, (%), 2004-2008
Figure 75: Biogen Idec, Current Ratio, 2004-2008
Figure 76: Biogen Idec, Debt to Equity Ratio, 2004-2008
Figure 77: Biogen Idec, Return on Equity, (%), 2004-2008
Figure 78: DuPont Analysis for Biogen Idec, 2004-2008
Figure 79: Therapeutic Focus of Biogen Idec R&D Pipeline, 2009
Figure 80: R&D Productivity for Biogen Idec, 2004-2008
Figure 81: Phase-wise Analysis of Biogen Idec R&D Pipeline, 2009
Figure 82: SWOT Analysis of CSL Limited
Figure 83: CSL Limited, Annual Revenue Forecasts, ($m), 2005-2013
Figure 84: CSL Limited, Net Income and R&D Expense, ($m), 2005-2009
Figure 85: CSL Limited, Earnings per Share, ($), 2005-2009
Figure 86: CSL Limited, Net Profit Margin, (%), 2005-2009
Figure 87: CSL Limited, Current Ratio, 2005-2009
Figure 88: CSL Limited, Debt to Equity Ratio, 2005-2009
Figure 89: CSL Limited, Return on Equity, (%), 2005-2009
Figure 90: DuPont Analysis for CSL Limited, 2005-2009
Figure 91: Therapeutic Focus of CSL Limited R&D Pipeline, 2009
Figure 92: R&D Productivity for CSL Limited, 2005-2009
Figure 93: Phase-wise Analysis of CSL Limited R&D Pipeline, 2009
Figure 94: SWOT Analysis of Celgene
Figure 95: Celgene, Annual Revenue Forecasts, ($m), 2004-2012
Figure 96: Celgene, Net Income and R&D Expense, ($m), 2004-2008
Figure 97: Celgene, Earnings per Share, ($), 2004-2008
Figure 98: Celgene, Net Profit Margin, (%), 2004-2008
Figure 99: Celgene, Current Ratio, 2004-2008
Figure 100: Celgene, Debt to Equity Ratio, 2004-2008
Figure 101: Celgene, Return on Equity, (%), 2004-2008
Figure 102: DuPont Analysis for Celgene, 2004-2008
Figure 103: Therapeutic Focus of Celgene R&D Pipeline, 2009
Figure 104: R&D Productivity for Celgene, 2004-2008
Figure 105: Phase-wise Analysis of Celgene R&D Pipeline, 2009
Figure 106: SWOT Analysis of Cephalon
Figure 107: Cephalon, Annual Revenue Forecasts, ($m), 2004-2012
Figure 108: Cephalon, Net Income and R&D Expense, ($m), 2004-2008
Figure 109: Cephalon, Earnings per Share, ($), 2004-2008
Figure 110: Cephalon, Net Profit Margin, (%), 2004-2008
Figure 111: Cephalon, Current Ratio, 2004-2008
Figure 112: Cephalon, Debt to Equity Ratio, 2004-2008
Figure 113: Cephalon, Return on Equity, (%), 2004-2008
Figure 114: DuPont Analysis for Cephalon, 2004-2008
Figure 115: Therapeutic Focus of Cephalon R&D Pipeline, 2009
Figure 116: R&D Productivity for Cephalon, 2004-2008
Figure 117: Phase-wise Analysis of Cephalon R&D Pipeline, 2009
Figure 118: SWOT Analysis of Actelion
Figure 119: Actelion, Annual Revenue Forecasts, ($m), 2004-2012
Figure 120: Actelion, Net Income and R&D Expense, ($m), 2004-2008
Figure 121: Actelion, Earnings per Share, ($), 2004-2008
Figure 122: Actelion, Net Profit Margin, (%), 2004-2008
Figure 123: Actelion, Current Ratio, 2004-2008
Figure 124: Actelion, Debt to Equity Ratio, 2004-2008
Figure 125: Actelion, Return on Equity, (%), 2004-2008
Figure 126: DuPont Analysis for Actelion, 2004-2008
Figure 127: Therapeutic Focus of Actelion R&D Pipeline, 2009
Figure 128: R&D Productivity for Actelion, 2004-2008
Figure 129: Phase-wise Analysis of Actelion R&D Pipeline, 2009
Figure 130: GBI Research Methodology

COMPANIES MENTIONED

Amgen
Genentech (Roche)
Gilead Sciences
UCB Pharma
Genzyme
Biogen Idec
CSL Limited
Celgene
Cephalon
Actelion Skip to top